In vivo BCMA CAR-T candidate shows promise in first human trial
EsoBiotec and Pregene Biopharma have dosed the first patient in an investigator-initiated clinical trial in China of ESO-T01 for relapsed/refractory multiple myeloma.
ESO-T01 is an immune shielded lentiviral vector that reprograms T lymphocytes in vivo into highly effective BCMA CAR-T cells.
The clinical trial is designed to evaluate the safety, tolerability and preliminary clinical activity, including in vivo reprogramming efficiency of a single intravenous infusion, across escalating doses of ESO-T01 in up to 24 patients with multiple myeloma.
Primary endpoints for the study include incidence and severity of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, dose-limiting toxicities, and treatment-associated adverse effects.
“Initial clinical observations with ESO-T01 indicate a favourable safety profile and promising efficacy already at the first dose level of 0.25E+09 transducing unit per patient, with pharmacokinetic characteristics comparable to autologous ex vivo CAR-T therapies,” said Principal Investigator Professor Heng MEI, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.
“The first patient received a starting dose of ESO-T01 without prior lymphodepletion. By Day 28, minimal residual disease in the bone marrow was undetectable, and the elevated free light chain levels secreted by tumour cells had normalised. No significant adverse events were reported during treatment.”
ESO-T01 has been developed by EsoBiotec using its immune-shielded cell specific lentiviral vector platform, ENaBL, combined with a BCMA CAR-T transgene developed by Pregene Biopharma.
“ESO-T01 has the potential to offer a simplified patient journey, with several benefits over current treatments for multiple myeloma that are often costly and have unfavorable side effects,” said EsoBiotec CEO Jean-Pierre Latere. “Our treatment does not require lymphodepletion, is immediately available to patients without any waiting time, and is administrated in a single intravenous dose that takes less than 10 minutes.”
Diana Spencer, Senior Digital Content Editor, DDW
